## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.3% below STRENGTH zone (4.0-10.0%); PEG 2.08 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($556.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch**
- Source: TradingView — Track All Markets | 20251222T130936 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. (TMO) has announced the enrollment of the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, an international initiative designed to generate real-world data on drug safety and effectiveness. This development is expected to support TMO stock's upward momentum despite a slight dip after the announcement, given the company's strong financial performance and the significant public health challenge posed by Alzheimer's disease. The registry aims to provide comprehensive insights into Alzheimer’s therapy outcomes, long-term safety, and treatment patterns.

**2. CCLA Investment Management Sells 16,843 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251222T100813 | Somewhat-Bullish | Relevance: 100%
- CCLA Investment Management decreased its holdings in Thermo Fisher Scientific Inc. by 5.3% in the third quarter, selling 16,843 shares. Despite CCLA's reduction, institutional ownership in Thermo Fisher remains high at 89.23%, with several other institutional investors significantly increasing their stakes. The company reported strong Q3 earnings, beating analyst estimates, and announced a new $5 billion share buyback program and a quarterly dividend.

**3. Thermo Fisher Scientific Inc. $TMO Stake Trimmed by Coho Partners Ltd.**
- Source: MarketBeat | 20251223T100818 | Somewhat-Bullish | Relevance: 100%
- Coho Partners Ltd. significantly reduced its stake in Thermo Fisher Scientific Inc. ($TMO) by 43.3% in Q3, now holding 69,551 shares valued at $33.73 million, which constitutes 4.3% of its portfolio. Despite this, Thermo Fisher reported strong Q3 earnings, beating estimates with $5.79 EPS and $11.12 billion in revenue, authorized a $5 billion share buyback, and declared a $0.43 quarterly dividend. However, insiders have been net sellers, offloading 149,271 shares worth approximately $86.5 million in recent months, even as analysts have raised price targets.

**4. Thermo Fisher Scientific Inc. $TMO Shares Sold by Cyndeo Wealth Partners LLC**
- Source: MarketBeat | 20251222T230909 | Somewhat-Bullish | Relevance: 100%
- Cyndeo Wealth Partners LLC significantly reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 57.7% in Q3, now holding 2,060 shares valued at $999,000. This comes alongside substantial insider selling, with CEO Marc N. Casper and COO Michel Lagarde offloading shares worth millions, bringing total insider sales to $86.5 million in the last 90 days. Despite this, institutional investors own 89.23% of the stock, and the company reported strong Q3 earnings, surpassing analyst estimates, authorizing a $5 billion share repurchase program, and announcing a quarterly dividend.

**5. The Zacks Analyst Blog Highlights Walmart, Wells Fargo, Thermo Fisher Scientific, Seneca Foods and NetSol Technologies**
- Source: Yahoo Finance Singapore | 20251222T150904 | Bullish | Relevance: 100%
- This Zacks Analyst Blog highlights five key companies: Walmart Inc. (WMT), Wells Fargo & Co. (WFC), Thermo Fisher Scientific Inc. (TMO), Seneca Foods Corp. (SENEA), and NetSol Technologies, Inc. (NTWK). It discusses their recent financial performance, market outperformance, strategic initiatives, and identifies potential challenges and opportunities for each. The report emphasizes the unique microcap research provided for Seneca Foods and NetSol Technologies.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.08 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.9B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.08 |
| Forward P/E | 23.5 |
| Current P/E | 25.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -0.3% (minimal 5-day change). Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.81), momentum weakening. RSI neutral at 56. OFD pattern: +FTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.33% (CS: 52) | Neutral |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | -0.81 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.018x | Above |
| vs SMA200 | 1.199x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $579.98
- **Stop Loss:** $556.42 (4.1% risk)
- **Target:** $603.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $28,999.00
- **Portfolio %:** 29.00%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*